22results about "Fibrinogen" patented technology

Disclosed is a method for filtering a fibrinogen composition, including the following steps: a) purifying the fibrinogen composition by chromatographic purification using an elution buffer comprising arginine; b) optionally, at least one step of filtering the fibrinogen composition obtained by chromatographic elution in step a), on a filter having a pore size of between 0.08 μm and 0.22 μm, c) filtering the fibrinogen composition obtained by chromatographic elution in step a), or optionally obtained in step b), on a symmetrical filter having a pore size of between 15 nm and 25 nm, and preferably between 18 nm and 22 nm, and d) recovering the resulting fibrinogen solution, the filtering method being carried out without adding arginine after step a), at a high capacity and without a prior freezing and / or thawing step.

The invention relates to a freeze drying method of instant fibrinogen, and belongs to the technical field of blood product preparation. The method comprises the steps of plasma pre-fusion, centrifugal separation, FI extraction, FI precipitation, dissolution and filtration, polyethylene glycol purification and separation, S / D inactivation, ethanol purification and separation, glycine purification and separation, ultrafiltration dialysis, preparation, degerming and subpackaging, freeze-drying and capping and the like. Wherein the freeze-drying process comprises four stages of pre-freezing, primary sublimation, desorption drying and plug pressing, and finally dry heat inactivation treatment is carried out. According to the method, efficient extraction and purification of fibrinogen are achieved by accurately controlling the temperature, the time, the pH value and the component proportion of various solutions in each step, and the obtained product has good instant dissolving performance and can be used in the medical fields of clinical hemostasis, tissue repair and the like.

The present invention provides a method for fractionating human plasma using, in some embodiments, the Cohn fractionation procedure. The improvement involves using bioactive enriched plasma as the starting material for the fractionation procedure.

Described herein are novel methods for fractionating and isolating platelets, platelet- and extracellular vesicle-derived growth factors, exosomes, globulins, fibrinogen and albumin, and methods of using the isolated platelets, platelet and extracellular vesicle-derived growth factors, exosomes, globulins, fibrinogen and albumin for regenerating tissue in a subject, treating fibrinogenemia or a clotting deficiency in a subject, treating ischemia and hypoxia, treating dry-eye syndrome, an orthopedic disorder, or a dental disorder in a subject. Also described herein are growth media for culturing mammalian (e.g., human) cells.

The application discloses a human fibrinogen high-efficiency separation device and relates to the technical field of biological medicine processing. The device comprises a tank body, a stirring mechanism and a conveying mechanism. The stirring mechanism comprises a stirring shaft and a stirring paddle. The conveying mechanism comprises a fluid channel and a liquid outlet. The stirring paddle is internally provided with a mounting cavity in communication with the fluid channel and the liquid outlet. A sliding part is slidably arranged in the mounting cavity. The device further comprises a magnetic driving assembly for driving the sliding part to reciprocatingly slide in the mounting cavity so as to extrude and spray the fluid from the liquid outlet. In the application, when the stirring paddle rotates to a specific position, the sliding part extrudes the mounting cavity under the magnetic attraction force of the permanent magnet, so that the pre-cooled ethanol is rapidly sprayed from the liquid outlet. The spraying mode makes the diffusion range of the pre-cooled ethanol in the blood plasma larger and the diffusion speed faster than those of the traditional mode, thereby avoiding the instantaneous concentration of the pre-cooled ethanol in the local part being too high, effectively preventing the denaturation of the protein in the blood plasma, avoiding the local ethanol concentration being too high and preventing the protein denaturation.

The invention relates to a method for separating and purifying fibrinogen with low impure protein, and belongs to the technical field of blood product production. The method comprises the following steps: preparing a raw material component I, dissolving and filtering an FI precipitate, dissolving with a dissolving solution A, and filtering to obtain a filtrate A; purifying and separating polyethylene glycol, adjusting the pH value of the filtrate A, adding polyethylene glycol to precipitate, dissolving the precipitate by using the dissolving solution B, and filtering; s / D inactivation: adding an S / D solution into the filtrate B for virus inactivation; ethanol purification and separation: adding ethanol to the inactivated solution to precipitate protein, dissolving the precipitate with a dissolving solution B, and filtering; purifying and separating glycine, adding glycine precipitation protein into the filtrate C, dissolving the precipitate by using the dissolving solution C, and filtering; carrying out ultrafiltration dialysis, and dialyzing and concentrating the filtrate D; preparation: diluting the stock solution to a proper concentration; the semi-finished product is subpackaged, freeze-dried and subjected to dry heat inactivation treatment. The method can effectively remove impure proteins, improve the purity of fibrinogen and ensure the product safety.

Ischemic heart disease is a leading cause of death and reduced quality of life worldwide. Although revascularization strategies significantly reduce mortality after acute myocardial infarction (MI), many patients with MI develop chronic heart failure over time. We previously reported that human recombinant ANGPTL4 counteracts ischemia-induced vascular endothelial growth factor signaling and disruption of endothelial cell-cell adhesion, thereby inhibiting vascular permeability. We were able to demonstrate that ANGPTL4 administration before MI resulted in protection of the coronary capillary network, no-reflow syndrome, and reduced infarct size in mice. We also demonstrated that the therapeutic effects observed with ANGPTL4 under ischemic conditions were caused by the FLD fragment, not the CCD fragment (WO 2016 / 110498). To further examine the therapeutic potential of the FLD fragment of ANGPTL4 at the onset of reperfusion, we herein used a porcine model, a clinically relevant model of acute myocardial infarction that can be easily and safely translated into patient treatment. We demonstrated that local (antegrade) delivery of the FLD ANGPTL4 to infarcted porcine hearts can efficiently target the lesion site in a clinically relevant manner. A single administration of the FLD of ANGPTL4 improved cardiac function, infarct size, fibrosis, and adverse remodeling parameters 28 days after MI. Short-term MI experiments, coupled with complementary mouse studies, demonstrated myocardial protection. Thus, a single administration of the FLD of ANGPTL4 can reduce ischemia-reperfusion injury and protect against adverse postischemic cardiac remodeling and subsequent ischemic heart failure.

The present invention is based on fibrin-derived peptides, which are therapeutic compounds for treating inflammatory complications of virally caused diseases, such as diffuse inflammation of the endothelium, also known as systemic endotheliitis or vasculitis and related disorders. The use of fibrin-derived peptides and analogs of these compounds has resulted in surprisingly effective patient recovery.

RNA molecules comprising a guide sequence portion having 17-20 nucleotides in the sequence of 17-20 contiguous nucleotides set forth in any one of SEQ ID NOs: 1-1990 and compositions, methods, and uses thereof.

The invention belongs to the technical field of blood product preparation, and particularly relates to a method for filtering, separating and purifying human fibrinogen from plasma. The method sequentially comprises the following steps: balancing cellulose, mixing the balanced cellulose with raw material plasma, adsorbing and filtering to obtain cellulose precipitate; leaching the cellulose precipitate, soaking the cellulose precipitate in the precipitate dissolving solution, and filtering to obtain filtrate; carrying out first ion exchange chromatography on the filtrate; and carrying out secondary ion exchange chromatography to obtain a protein solution with fibrinogen purity of more than 80%. According to the technical scheme, the technical problems that in the prior art, the process steps of purifying and enriching the human fibrinogen from the plasma cryoprecipitate are tedious, and the utilization rate of the human fibrinogen is not ideal can be solved. According to the cryoprecipitated protein solution prepared by the method, VIII factor, vWF factor and fibrinogen products can be separated at the same time through chromatography, the utilization rate of plasma protein is improved, and the method has ideal popularization and application prospects.

The invention provides a separation and purification method of platelets and application of the platelets obtained through separation and purification in PRP or PRF. The method comprises the following steps: carrying out chemical cross-linking on an anti-erythrocyte antibody and an anti-leukocyte antibody to prepare an antibody compound, incubating the antibody compound and a blood sample to obtain a mixed solution, centrifuging, collecting supernate, and removing parenchyma cells and agglomerates to obtain the platelets. The platelet in the blood sample is separated and purified by using the method provided by the invention, the recovery rate of the platelet is greater than or equal to 92%, the activity is improved by more than 30% compared with that of a centrifugal method, the residual leukocyte is less than 1 * 10 < 6 > / mL, the residual erythrocyte is less than 5 * 10 < 7 > / mL, the clinical infusion standard is reached, the separation and purification operation steps are simple, the whole process time is less than or equal to 20 minutes, the platelet separation and purification efficiency is improved, and the cost is reduced. And the cost is reduced by more than 50%. The PRP or PRF prepared from the platelets separated and purified by the method provided by the invention can be applied to the fields of department of stomatology, maxillofacial surgery, orthopedics, plastic surgery and the like.

This document provides methods that can treat and / or prevent pneumothorax. For example, this document provides methods for delivering an aerosolized agent to reduce air leakage at a site in a respiratory tract of patient.

The invention relates to a preparation process for extracting human fibrinogen from a component I, and belongs to the technical field of blood products. The process comprises the following steps: dissolving an FI precipitate in a dissolving solution A containing sodium citrate, lysine hydrochloride and heparin sodium, and filtering to obtain a filtrate A; adding PEG (Polyethylene Glycol) into the filtrate A until the final concentration is 5%, purifying and separating, collecting PEG precipitate, dissolving and filtering to obtain filtrate B; adding polysorbate 80 and tributyl phosphate into the filtrate B to carry out S / D inactivation; cooling the inactivated liquid, adding an ethanol solution for purification and separation, collecting the precipitate, and dissolving to obtain a filtrate C; adding glycine into the filtrate C until the final concentration is 1.8 mol / L, performing purification and separation, collecting precipitates, and dissolving to obtain filtrate D; performing ultrafiltration dialysis on the filtrate D to obtain a stock solution; and diluting the stock solution to a proper concentration, sterilizing, filtering, sub-packaging, freeze-drying, and carrying out dry heat inactivation treatment to obtain a finished product. The method is simple in process and low in cost, and the prepared human fibrinogen is high in purity, good in safety and suitable for clinical hemostasis and tissue repair.

The invention belongs to the technical field of glycoprotein, and particularly relates to a method for preparing human fibrinogen. The method comprises the following steps: by taking a low-temperature ethanol method component I as a raw material, carrying out PEG (Polyethylene Glycol) precipitation one-step purification to enable the product to reach 90% or more, carrying out S / D virus inactivation, removing an S / D inactivator by utilizing chromatographic separation, replacing salt in an eluent by utilizing a dialysis buffer solution, degerming, freeze-drying and carrying out dry heat inactivation to obtain a finished product. Mild PEG precipitation separation is adopted for crude preparation of the product, compared with a traditional low-temperature ethanol method, the change of a protein structure caused by ethanol precipitation is not needed, the molecular structure tends to be natural, detection shows that the redissolution time of the product is within 5 min, the purity reaches up to 90% or above, and the product can be used for clinical blood coagulation and can also be used for a component of blood coagulation gel.

Biosensors for detecting presence or amount of a charged analyte in a sample are provided. The biosensor can include a core component and a charged biopolymer component that includes one or more layers of charged biopolymer. The outermost layer of the charged biopolymer component is oppositely charged relative to the charged analyte and capable of binding to the charged analyte. The biosensor can comprise two or more layers of alternating oppositely-charged biopolymers, with each layer being oppositely charged relative to the adjacent layer. Apparatuses coupled to the biosensor for quantitating the signals generated by binding of the biosensor to the charged analyte, as well as methods for detecting presence or amount of a charged analyte in a sample using the biosensor are also provided.

Provided are an apparatus for forming a reinforcing layer on a sheet-shaped cell culture, a method for forming a reinforcing layer on a sheet-shaped cell culture, and a program for forming a reinforcing layer on a sheet-shaped cell culture, which can prevent wrinkles from occurring in the sheet-shaped cell culture when a reinforcing layer is formed on the sheet-shaped cell culture, and which enable stabilization of product quality of the laminate compared to when the sheet-shaped cell culture is stretched manually. [Solution] The forming device 200 is an apparatus equipped with a processing unit 210 that performs processing to form a reinforcing layer 30 made of fibrin gel on a sheet-shaped cell culture 10, and the processing unit has one or more contact units 220, 230 with lattice-shaped contact surfaces 221a, 231a configured to be able to come into contact with the sheet-shaped cell culture, and the contact units are configured to be able to eject fibrinogen solution and / or thrombin solution onto the sheet-shaped cell culture that has come into contact with the contact surfaces.

The present disclosure provides binding proteins that target tau, as well as bispecific binding proteins that target tau and a central nervous system protein (e.g., transferrin receptor 1). Also provided is the use of these binding proteins to treat tauopathies.

In the present invention, we identified the hepatokine FGL1 as a previously unreported hepcidin suppressor that is highly induced in the liver in response to hypoxia during recovery from anemia and in thalassemia mice. We demonstrated that FGL1 is a potent suppressor of hepcidin in vitro and in vivo. Deficiency of Fgl1 in mice (Fgl1- / -) results in lower hepcidin repression after hemorrhage. Finally, we clearly demonstrated that FGL1 is a BMP antagonist that directly binds to BMP6 and impairs the canonical BMP-SMAD signaling cascade that controls hepcidin regulation. Therefore, the present invention relates to methods for preventing or treating iron overload-related diseases by targeting the hepatokine FGL1, a novel hepcidin repressor.

The invention belongs to the technical field of blood product preparation, and particularly relates to a solution for blood product preparation and application of the solution in preparation of vWF factor and VIII factor products. The solution for blood product preparation comprises a first eluent for ion exchange chromatography and a diluent for diluting the product obtained by ion exchange chromatography. The first component contains sodium citrate, alanine, glycine and polysorbate 80; the latter is a solution containing trihydroxymethyl aminomethane, alanine, glycine, mannitol and cane sugar. According to the scheme, the technical problem that the specific activity, the stability and the like of the vWF factor and the factor VIII obtained by a cellulose-based plasma cryoprecipitation process are difficult to effectively improve can be solved, and the product quality and the production efficiency of the VIII / vWF factor can be effectively improved when the method is applied to production practice; the method is a technical key point for improving a cellulose-based cryoprecipitation preparation process and a three-step chromatography process for VIII / vWF factor preparation, and has ideal popularization and application prospects.

The present invention relates to an isolated recombinant polypeptide comprising a fibrinogen gamma chain and a His tag. The present invention also relates to a nucleic acid encoding said polypeptide, a vector comprising said nucleic acid, a host cell, preferably a bacterial host cell, comprising said nucleic acid or vector, a biological hybrid material comprising a conjugate comprising said polypeptide, uses of the above, and a method of manufacturing said polypeptide.

The invention relates to a hybrid molecule comprising at least one antibody Fc fragment covalently bound to at least one fibrin-derived peptide having at least one citrullyl residue, the uses of such a hybrid molecule, and the method for producing same.

The present invention provides CD3, its pharmaceutical composition, and polyspecific antibodies that selectively bind to PSMA and effector cell antigens such as nucleic acids, as well as methods for producing and discovering them. [Solution] The present invention provides an isolated polypeptide or polypeptide complex according to formula I:A2-A1-L1-P1-H1, wherein A1 comprises a first antigen-recognizing molecule that binds to an effector cell antigen, P1 comprises a peptide that binds to A1, L1 comprises a linking portion that connects A1 to P1 and is a substrate for a tumor-specific protease, H1 comprises a half-life extension molecule, and A2 comprises a second antigen-recognizing molecule that binds to prostate-specific membrane antigen (PSMA).